AZ 628

• Description :

  AZ 628 is a pan-Raf kinase inhibitor with IC50s of 105, 34 and 29 nM for B-Raf, B-RafV600E, and c-Raf-1, respectively.

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H315, H319, H335

• Target :

  Apoptosis; Raf

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; MAPK/ERK Pathway

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/AZ-628.html

• Purity :

  99.44

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  O=C1N(C)C=NC2=C1C=C(C=C2)NC3=C(C)C=CC(NC(C4=CC(C(C#N)(C)C)=CC=C4)=O)=C3

• Molecular Formula :

  C27H25N5O2

• Molecular Weight :

  451.52

• Precautions :

  H301, H315, H319, H335

• References & Citations :

  [1]Khazak V, et al. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets. 2007 Dec;11 (12) :1587-609.|[2]Lau KS, et al. BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner. PLoS One. 2012;7 (7) :e41343.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  B-Raf; C-Raf

• CAS Number :

  [878739-06-1]